A0A6G7KRG6 (A0A6G7KRG6_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Replicase polyprotein 1a UniProtKBInterProInteractive Modelling
4405 aa; Sequence (Fasta) ;
2 identical sequences: Severe acute respiratory syndrome coronavirus 2: P0DTC1, A0A6G6A224
It is possible new templates exist for this target since these models were created.
Available Structures
70 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Structure of the SARS-COV2 PLpro (C111S) in complex with a dimeric Ubv that inhibits activity by an… |
Heteromer P0DTC1; P62987; | 1×ZN; 2×BR; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 1 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×MTA; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 11 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H4D; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 5 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H28; 2×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 7 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3D; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 4 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3E; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 6 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3A; 2×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 8 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H29; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 10 |
Heteromer P0DTC1; P0DTD1; | 1×A1H4B; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 9 |
Heteromer P0DTC1; P0DTD1; | 1×A1H4C; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3B; 3×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3C; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 RNA E-RTC complex with RMP-nsp9 and GMPPNP |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 1×GNP; 1×MG; 1×F86; | ||||
| Assess | ||||||
| SARS-CoV-2 E-RTC complex with RNA-nsp9 |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 2×MN; | ||||
| Assess | ||||||
| Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mecha… |
Heteromer P0DTC1; P0DTD1; | 13×ZN; 1×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 E-RTC bound with MMP-nsp9 and GMPPNP |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 1×GNP; 1×6GS; | ||||
| Assess | ||||||
| SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction |
Heteromer P0DTC1; P0DTD1; | |||||
| Assess | ||||||
| Structure of compound 12 bound to SARS-CoV-2 main protease | homo-2-mer | 2×XJ9; 4×CL; 2×BR; 4×EDO; 1×NA; | ||||
| Assess | ||||||
| Structure of compound 7 bound to SARS-CoV-2 main protease | homo-2-mer | 2×XI0; 1×GOL; 2×BR; 3×CL; 1×EDO; 1×NA; | ||||
| Assess | ||||||
| Structure of compound 11 bound to SARS-CoV-2 main protease | homo-2-mer | 2×XHW; 1×PGE; 2×BR; 2×CL; 2×GOL; 1×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH FRAGMENT F01 | homo-2-mer | 4×NA; 4×DMS; 2×5P9; | ||||
| Assess | ||||||
| Structure of compound 8 bound to SARS-CoV-2 main protease | homo-2-mer | 2×XH9; 1×CL; 1×DMS; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro-S144A mutant in complex with 13b-K | homo-2-mer | 2×O6K; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro in complex with cyclic peptide GM4 including unnatural amino a… | homo-2-mer | 2×PEG; 1×DMS; 2×EDO; 1×PGE; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365097A | homo-2-mer | 2×WTV; 2×GOL; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A | homo-2-mer | 2×WTE; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with SY110 | homo-2-mer | 2×LVX; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro-S144A mutant, free enzyme | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with CCF0058981 | homo-2-mer | 1×XIU; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with Hit-1 | homo-2-mer | 2×LV0; 4×DMS; | ||||
| Assess | ||||||
| Mpro from SARS-CoV-2 with 298Q mutation | homo-2-mer | 2×GOL; 2×EDO; 2×NA; 4×SO4; | ||||
| Assess | ||||||
| Mpro from SARS-CoV-2 with 4A mutation | homo-2-mer | |||||
| Assess | ||||||
| Mpro from SARS-CoV-2 with 4Q mutation | homo-2-mer | |||||
| Assess | ||||||
| Mpro from SARS-CoV-2 with R4A R298A double mutations | homo-2-mer | 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with GC376 | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease Y54C mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with S217622 | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease D48N mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease D48N mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 papain-like protease (PLPro) C112S mutant | monomer | 1×ZN; 1×PO4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like protease PLpro in complex with 3, 4-Dihydroxybenzoic acid, meth… | monomer | 1×HE9; 2×GOL; 1×ZN; 4×PO4; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-89 | monomer | 1×ZN; 2×SO4; 1×XT7; 1×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-83 | monomer | 1×ZN; 4×SO4; 2×BO3; 1×Y54; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-24 | monomer | 1×XR8; 1×ZN; 2×SO4; 3×BO3; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun11941 | monomer | 1×XWO; 1×ACT; 4×ZN; 4×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) complex with inhibitor Jun12129 | monomer | 1×Y2R; 1×PEG; 1×PGE; 1×ACT; 8×ZN; 3×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Papain-like protease (PLpro) with Inhibitor Jun12682 | monomer | 1×XB5; 6×ZN; 2×CL; | ||||
| Assess | ||||||
| SARS CoV-2 PLpro in complex with inhibitor 3k | monomer | 1×S88; 4×ZN; 1×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12199 | monomer | 1×XYI; 2×PEG; 5×ZN; 4×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12197 | monomer | 1×Y2I; 6×ZN; 3×CL; | ||||
| Assess | ||||||
| SARS-Cov-2 papain-like protease (PLpro) with inhibitor Jun12162 | monomer | 1×XYR; 1×ACT; 6×ZN; 3×CL; 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12145 | monomer | 1×Y2N; 1×DMS; 1×ACT; 5×ZN; 3×CL; | ||||
| Assess | ||||||
| SARS-COV2 Main Protease in complex with inhibitor MG-131 | monomer | 1×I8H; 1×NA; | ||||
| Assess | ||||||
| SARS-COV2 Main Protease in complex with inhibitor MG78 | monomer | 1×I70; 1×CL; 2×NA; | ||||
| Assess | ||||||
| Mpro from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with beta-methyl-ADP | monomer | 1×OH9; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with 2'-deoxy-ADPR | monomer | 1×OHR; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with 2'-deoxy-2'-fluoro-ADPR | monomer | 1×OI3; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with beta-ethyl-ADP | monomer | 1×OIG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with 8Br-ADPR | monomer | 1×OI6; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in the apo form | monomer | 1×CL; 1×MPO; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with alpha-1-O-Me-ADPR | monomer | 1×RVK; | ||||
| Assess | ||||||
32 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5rfv.1.B | homo-2-mer | 0.91 | 2×T8J; | 100.00 | ||
| Assess | ||||||
| 5r7z.1.B | homo-2-mer | 0.91 | 2×HWH; | 100.00 | ||
| Assess | ||||||
| 2z9j.1.A | homo-2-mer | 0.89 | 2×DTZ; | 96.08 | ||
| Assess | ||||||
| 6lu7.1.B | homo-2-mer | 0.89 | 100.00 | |||
| Assess | ||||||
| 6y2g.1.A | homo-2-mer | 0.88 | 1×GLY; 2×O6K; | 100.00 | ||
| Assess | ||||||
| 2a5i.1.B | homo-2-mer | 0.87 | 2×AZP; | 96.08 | ||
| Assess | ||||||
| 7msw.1.A | monomer | 0.84 | 3×ZN; | 100.00 | ||
| Assess | ||||||
| 6ywk.3.A | monomer | 0.84 | 100.00 | |||
| Assess | ||||||
| 6m71.1.B | monomer | 0.80 | 100.00 | |||
| Assess | ||||||
| 6w9c.1.A | monomer | 0.80 | 1×ZN; | 100.00 | ||
| Assess | ||||||
| 2g9t.1.A | homo-12-mer | 0.80 | 24×ZN; | 97.12 | ||
| Assess | ||||||
| 3e9s.1.A | monomer | 0.79 | 1×TTT; 1×ZN; | 82.86 | ||
| Assess | ||||||
| 7cmd.4.A | monomer | 0.79 | 1×TTT; 1×ZN; | 100.00 | ||
| Assess | ||||||
| 7jlt.1.A | monomer | 0.79 | 100.00 | |||
| Assess | ||||||
| 2w2g.1.A | monomer | 0.79 | 75.00 | |||
| Assess | ||||||
| 6wuu.2.A | monomer | 0.79 | 1×ACE; 1×ZN; | 99.69 | ||
| Assess | ||||||
| 1qz8.1.A | homo-2-mer | 0.79 | 97.35 | |||
| Assess | ||||||
| 6w4b.1.A | homo-2-mer | 0.79 | 100.00 | |||
| Assess | ||||||
| 2ahm.1.H | monomer | 0.77 | 97.47 | |||
| Assess | ||||||
| 6w4h.1.B | monomer | 0.77 | 2×ZN; | 100.00 | ||
| Assess | ||||||
| 7jlt.1.D | monomer | 0.76 | 100.00 | |||
| Assess | ||||||
| 6nur.1.B | monomer | 0.76 | 97.47 | |||
| Assess | ||||||
| 7k7p.1.A | monomer | 0.76 | 100.00 | |||
| Assess | ||||||
| 2kqv.1.A | monomer | 0.75 | 78.13 | |||
| Assess | ||||||
| 2ahm.1.B | monomer | 0.75 | 98.80 | |||
| Assess | ||||||
| 1uw7.1.B | homo-2-mer | 0.73 | 97.35 | |||
| Assess | ||||||
| 3vcb.1.A | homo-2-mer | 0.72 | 61.36 | |||
| Assess | ||||||
| 2kqw.1.A | monomer | 0.71 | 80.22 | |||
| Assess | ||||||
| 2ahm.1.E | monomer | 0.70 | 97.47 | |||
| Assess | ||||||
| 6m71.1.D | monomer | 0.70 | 100.00 | |||
| Assess | ||||||
| 2k87.1.A | monomer | 0.69 | 81.74 | |||
| Assess | ||||||
| 6zoj.1.8 | monomer | 0.67 | 100.00 | |||
| Assess | ||||||